KOLM THERAPEUTICS
DEAD

Serial Number

98541872

Owner

Kolm Therapeutics Inc.

Attorney

Aaron D. Hendelman

Filing Date

May 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

KOLM THERAPEUTICS Trademark

Serial Number: 98541872

KOLM THERAPEUTICS is a trademark filed by Kolm Therapeutics Inc. on May 9, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Kolm Therapeutics Inc.

4 Research Drive
Woodbridge, CT 06525

Entity Type: 03

Trademark Details

Filing Date

May 9, 2024

Registration Date

Not Registered

Goods & Services

therapeutic pharmaceuticals for the treatment of cancer and autoimmune diseases; pharmaceutical products for the prevention and treatment of cancer; anti-cancer preparations; pharmaceutical preparations for the prevention and treatment of immunologic diseases, namely, autoimmune diseases; pharmaceuticals comprising small molecules for the treatment of cancer and autoimmune diseases; none of the foregoing related to cosmetics, skin care products, supplements, nutraceutical preparations, bacterial preparations, antioxidants, or foodstuffs, and none of the foregoing for the treatment or prevention of atopic dermatitis, skin diseases, damaged skin, damaged tissues, allergies, hay fever, headaches, motion sickness, hepatitis, joint pain, bruises, injuries, infections, wounds, nerve disorders, menopausal disorders, obesity, ophthalmologic diseases, musculoskeletal disorders, cardiac disorders, kidney diseases, respiratory organ diseases, digestive organ diseases, central nervous system diseases or disorders, gastro-intestinal diseases, or inflammatory diseases or disorders

conducting scientific research for others for medical purposes in the fields of oncology and autoimmune diseases; conducting medical and scientific research and development of therapeutics for others for the treatment of cancer and autoimmune diseases; conducting medical and scientific research and development in the field of small molecule drug discovery for others in the fields of oncology and autoimmune diseases; conducting medical and scientific research for others in the field of cancer treatment and diagnosis; conducting medical and scientific research for others in the field of pharmaceuticals for the treatment of cancer and autoimmune diseases; pharmaceutical products development for others in the fields of oncology and autoimmune diseases; drug discovery services for others in the fields of oncology and autoimmune diseases; conducting pharmaceutical research and development services for others in the fields of oncology and autoimmune diseases; conducting medical and scientific research and development for others in the field of precision medicine for the treatment of cancer and autoimmune diseases; none of the foregoing related to cosmetics, skin care products, supplements, nutraceutical preparations, bacterial preparations, antioxidants, or foodstuffs, and none of the foregoing for the treatment or prevention of atopic dermatitis, skin diseases, damaged skin, damaged tissues, allergies, hay fever, headaches, motion sickness, hepatitis, joint pain, bruises, injuries, infections, wounds, nerve disorders, menopausal disorders, obesity, ophthalmologic diseases, musculoskeletal disorders, cardiac disorders, kidney diseases, respiratory organ diseases, digestive organ diseases, central nervous system diseases or disorders, gastro-intestinal diseases, or inflammatory diseases or disorders; all of the foregoing excluding providing on-line non-downloadable software for pharmaceutical companies that allows them to research and track key opinion leaders in their therapeutic field of interest

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 9, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 9, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 28, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 28, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 28, 2025 CNRT
WITHDRAWAL OF ATTORNEY GRANTED
Jul 1, 2025 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Jul 1, 2025 WOAR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 20, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 20, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 20, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 9, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 9, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Nov 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Nov 24, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 22, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2024 NWOS
NEW APPLICATION ENTERED
May 9, 2024 NWAP